![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Prevalence of Pretreatment NS5A and NS5B Resistance-Associated Variants and Genetic Variation Within HCV Subtypes Across Different Countries/Gilead-Study
|
|
|
Reported By Jules Levin
EASL 2015 April 22-26 Vienna Austria
Evguenia S. Svarovskaia,1 Stefan Zeuzem,2 Charlotte Hedskog,1 Ross Martin,1 Diana M. Brainard,1 Michael D. Miller,1 Ed Gane,3 Hongmei Mo1
1Gilead Sciences, Inc., Foster City, California, USA; 2Goethe-Universität, Frankfurt am Main, Germany; 3Auckland Clinical Studies Ltd, Auckland, New Zealand
![EASL1.gif](../images/043015/043015-1/EASL1.gif)
![EASL2.gif](../images/043015/043015-1/EASL2.gif)
![EASL3.gif](../images/043015/043015-1/EASL3.gif)
![EASL4.gif](../images/043015/043015-1/EASL4.gif)
![EASL5.gif](../images/043015/043015-1/EASL5.gif)
![EASL6.gif](../images/043015/043015-1/EASL6.gif)
![EASL7.gif](../images/043015/043015-1/EASL7.gif)
![EASL8.gif](../images/043015/043015-1/EASL8.gif)
![EASL9.gif](../images/043015/043015-1/EASL9.gif)
![EASL10.gif](../images/043015/043015-1/EASL10.gif)
References
1. Messina JP, et al. Hepatology 2015;61:77-87;
2. Svarovskaia ES, et al. J Clin Microbiol 2012;50:3267-74;
3. Svarovskaia ES, et al. Clin Infect Dis 2014;59:1666-74;
4. Donaldson EF, et al. Hepatology 2015;61:56-65;
5. Zhdanov K, et al. APASL 2015, oral presentation.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|